TIMP-3 Muteins with Mutations for Extended Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The development of TIMP-3 as a therapeutic inhibitor of MMP activity is hindered by challenges in production and its short half-life, which limits its effectiveness in treating conditions like osteoarthritis and cardiovascular conditions.
Innovation Solution
The development of TIMP-3 muteins with specific mutations, such as K45N, V47T, T63E, H78E, K45S, F57N, and K133S, which enhance expression levels, reduce binding to extracellular matrix, and alter binding affinities, thereby improving production and pharmacokinetic properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant TIMP-3 is produced, then therapeutic inhibition of MMP activity is achieved, but production challenges and short half-life limit effectiveness
Solution Approach 1:
The patent applies parameter changes by introducing specific amino acid mutations (K45N, V47T, T63E, H78E, K45S, F57N, K133S) into the TIMP-3 protein sequence. These mutations alter the protein's biochemical parameters to reduce binding to the extracellular matrix and increase half-life, thereby improving therapeutic effectiveness without compromising MMP inhibition capability.
2Reliability
If TIMP-3 is used to inhibit MMP activity, then cartilage degradation is prevented, but production challenges hinder development
Solution Approach 1:
The patent modifies production-related parameters by introducing mutations (K45N, V47T, T63E, H78E, K45S, F57N, K133S) that alter the protein's interaction with the extracellular matrix and cellular uptake mechanisms. These changes facilitate easier recombinant production while maintaining cartilage protection efficacy.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.